drugset / Trial / NCT00556998

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

NCT00556998

Phase 2 Completed 26 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.

Timeline

Start
2008-06
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 4 mg/kg Intravenous
Subject Voriconazole Small molecule 300 mg Intravenous

Indications

No indication recorded.